Welcome!

News Feed Item

Frost & Sullivan Presents Goodwin Biotechnology with the Global Customer Value Leadership Award for Mammalian Biologics Contract Manufacturing

-- Goodwin Biotechnology pioneered best-in-class practices for the development of complex Biopharmaceuticals and Antibody Drug Conjugates (ADCs)

LONDON, Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology's reputation as one of the most trusted providers of mammalian contract manufacturing and development services has been built on more than 20 years of experience in the bioprocess development and cGMP manufacturing of mammalian cell culture-derived monoclonal antibodies (mAbs), vaccines, and recombinant proteins, and more than 10 years pioneering the field of bioconjugation.

Goodwin Biotechnology championed the concept of 'full integration' in the biopharmaceutical contract manufacturing space. It is a one-stop shop, offering its partners a comprehensive range of services from cell line development and proof-of-concept projects to bioprocess development and the manufacture of material for preclinical / Tox studies as well as early to late phase clinical trials.

Goodwin Biotechnology strives to be a highly flexible partner with its clients by finding customized solutions for the distinctive needs of every project and ensuring smooth implementation all throughout the lifecycle of an engagement. Furthermore, it has enhanced its brand value on a global basis by maintaining high levels of transparency and responsiveness while focusing on quality, and working within budgets and timelines.

The core services offered by Goodwin Biotechnology include cell line development through collaborations, cell culture and purification process development, cell banking, process scale-up, engineering runs for toxicology study materials, and strict adherence to current good manufacturing practices (cGMP) for manufacturing and providing Fill / Finish services for biopharmaceutical candidates used in human clinical trials. The company has also established best-in-class processes for the production of antibody drug conjugates (ADCs), cytotoxic ADCs (CADCs), antibody-chelator conjugates (for radioimmunoconjugates) and other bioconjugates.

"These core services are fully complemented and enhanced by the company's analytical and formulation development capabilities as well as its quality assurance, quality control, regulatory and project management capabilities," said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "The complete and fully-integrated services offered by Goodwin Biotechnology reduce the supply chain complexities and timeline for clients to efficiently meet their preclinical and clinical needs."

"We at Goodwin Biotechnology are honored to be recognized for such a prestigious award, which showcases our orientation towards providing our clients with the best overall value proposition," noted Karl Pinto, CEO of Goodwin Biotechnology. "It is a testament to the company's rich and distinguished history, coupled with its innovative, state-of-the-art technologies, and highly skilled scientists that enables us to meet the expectations of customers across the globe and at various stages of their respective product development cycles. Having addressed challenges pertaining to the manufacturing of complex biological molecules, such as monoclonal antibodies, recombinant therapeutic proteins, vaccines and cytotoxic ADCs (CADCs), Goodwin Biotechnology helps our clients formulate a strategic approach with particular emphasis on critical protein product characterization, process development, and cGMP manufacturing for regulatory compliance."

"Goodwin Biotechnology's time-tested expertise with various host cell types and process optimisation techniques enables seamless technology transfers between R&D and GMP manufacturing for clinical studies," added Chidambaram. "It is one of the few contract manufacturing organisations to have installed capabilities for a number of robust and reproducible cell cultivation technologies, including disposable bioreactors such as, WAVE, perfusion, and stainless steel tank bioreactors."

At the start of every project, Goodwin Biotechnology focuses on optimising and refining the processes to maximize productivity and ensure seamless scale up. Towards that end, the company has hands-on experience in several chromatographic techniques including affinity, ion exchange, hydrophobic interaction, mixed mode, and size-exclusion chromatography. In addition, its ultrafiltration/diafiltration (UF/DF) processes use tangential flow filtration (TFF) technologies in both flat-plate and hollow-fiber formats.

Goodwin Biotechnology also addresses complex issues associated with antibody drug conjugates, including linker design, drug payload selection, and antibody stability in the production of multi-gram lots of conjugated antibodies used globally in clinical trials. Apart from its rich and varied expertise in protein modification through chemical conjugation and enzymatic digestion methods, Goodwin Biotechnology also offers unique specialties such as the production of Fab and F(ab')2 fragments and their subsequent purification as per client specifications.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognises the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Goodwin Biotechnology

Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs) and other Biologic Drug Conjugates for early and late stage clinical trials. By working with Goodwin Biotechnology, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at http://www.GoodwinBio.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:   Start the discussion 
Join Us:      Join our community 
Subscribe:    Newsletter on "the next big thing" 
Register:     Gain access to visionary innovation

Contact:

Frost & Sullivan

Goodwin Biotechnology, Inc.

Melanie Parkinson

Robin McCallum, MSc

Best Practices, Frost & Sullivan

Manager of Business Development

E: [email protected]

[email protected]

P: +44 (0) 207 915 7867

+1 954-327-9656

T: @MelanieFrostBPA

www.GoodwinBio.com

www.awards.frost.com

[email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to impr...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.